Literature DB >> 34824471

Disease modification is not all - we need symptomatic therapies for Alzheimer disease.

Jeffrey Cummings1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 34824471      PMCID: PMC9011363          DOI: 10.1038/s41582-021-00591-9

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  Predictors of family caregiver ratings of patient quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study.

Authors:  Gary Naglie; David B Hogan; Murray Krahn; Sandra E Black; B Lynn Beattie; Christopher Patterson; Chris Macknight; Morris Freedman; Michael Borrie; Anna Byszewski; Howard Bergman; David Streiner; Jane Irvine; Paul Ritvo; Janna Comrie; Matthew Kowgier; George Tomlinson
Journal:  Am J Geriatr Psychiatry       Date:  2011-10       Impact factor: 4.105

2.  Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.

Authors:  Paul B Rosenberg; Krista L Lanctôt; Lea T Drye; Nathan Herrmann; Roberta W Scherer; David L Bachman; Jacobo E Mintzer
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

3.  Neuropathologic correlates of apathy in Alzheimer's disease.

Authors:  Gad A Marshall; Lynn A Fairbanks; Sibel Tekin; Harry V Vinters; Jeffrey L Cummings
Journal:  Dement Geriatr Cogn Disord       Date:  2006-01-02       Impact factor: 2.959

4.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Authors:  Cheryl L P Vigen; Wendy J Mack; Richard S E Keefe; Mary Sano; David L Sultzer; T Scott Stroup; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; Pierre N Tariot; Ling Zheng; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

5.  Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

Authors:  Gil D Rabinovici
Journal:  N Engl J Med       Date:  2021-07-28       Impact factor: 91.245

6.  Trial of Pimavanserin in Dementia-Related Psychosis.

Authors:  Pierre N Tariot; Jeffrey L Cummings; Maria E Soto-Martin; Clive Ballard; Deniz Erten-Lyons; David L Sultzer; Davangere P Devanand; Daniel Weintraub; Bradley McEvoy; James M Youakim; Srdjan Stankovic; Erin P Foff
Journal:  N Engl J Med       Date:  2021-07-22       Impact factor: 91.245

7.  Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.

Authors:  Jacobo Mintzer; Krista L Lanctôt; Roberta W Scherer; Paul B Rosenberg; Nathan Herrmann; Christopher H van Dyck; Prasad R Padala; Olga Brawman-Mintzer; Anton P Porsteinsson; Alan J Lerner; Suzanne Craft; Allan I Levey; William Burke; Jamie Perin; David Shade
Journal:  JAMA Neurol       Date:  2021-11-01       Impact factor: 29.907

8.  Diagnostic criteria for apathy in neurocognitive disorders.

Authors:  David S Miller; Philippe Robert; Larry Ereshefsky; Lawrence Adler; Daniel Bateman; Jeff Cummings; Steven T DeKosky; Corinne E Fischer; Masud Husain; Zahinoor Ismail; Judith Jaeger; Alan J Lerner; Abby Li; Constantine G Lyketsos; Valeria Manera; Jacobo Mintzer; Hans J Moebius; Moyra Mortby; Didier Meulien; Stephane Pollentier; Anton Porsteinsson; Jill Rasmussen; Paul B Rosenberg; Myuri T Ruthirakuhan; Mary Sano; Carla Zucchero Sarracini; Krista L Lanctôt
Journal:  Alzheimers Dement       Date:  2021-05-05       Impact factor: 16.655

9.  Alzheimer's disease drug development pipeline: 2021.

Authors:  Jeffrey Cummings; Garam Lee; Kate Zhong; Jorge Fonseca; Kazem Taghva
Journal:  Alzheimers Dement (N Y)       Date:  2021-05-25
  9 in total
  1 in total

Review 1.  Personalized Management and Treatment of Alzheimer's Disease.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Olaia Martínez-Iglesias; Lola Corzo; Natalia Cacabelos; Rocío Pego; Juan C Carril
Journal:  Life (Basel)       Date:  2022-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.